Logo image of BDMD

BAIRD MEDICAL INVESTMENT HOL (BDMD) Stock Fundamental Analysis

NASDAQ:BDMD - Nasdaq - KYG0705H1039 - Common Stock - Currency: USD

5.415  -0.14 (-2.48%)

After market: 5.5 +0.08 (+1.57%)

Fundamental Rating

1

Overall BDMD gets a fundamental rating of 1 out of 10. We evaluated BDMD against 190 industry peers in the Health Care Equipment & Supplies industry. BDMD may be in some trouble as it scores bad on both profitability and health. BDMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BDMD had negative earnings in the past year.
In the past year BDMD has reported a negative cash flow from operations.
BDMD Yearly Net Income VS EBIT VS OCF VS FCFBDMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -2M -4M -6M

1.2 Ratios

BDMD's Return On Assets of -27.85% is in line compared to the rest of the industry. BDMD outperforms 47.37% of its industry peers.
Looking at the Return On Equity, with a value of -194.92%, BDMD is doing worse than 73.68% of the companies in the same industry.
Industry RankSector Rank
ROA -27.85%
ROE -194.92%
ROIC N/A
ROA(3y)-4.55%
ROA(5y)N/A
ROE(3y)-9.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDMD Yearly ROA, ROE, ROICBDMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDMD Yearly Profit, Operating, Gross MarginsBDMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for BDMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BDMD has a worse debt to assets ratio.
BDMD Yearly Shares OutstandingBDMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M 25M
BDMD Yearly Total Debt VS Total AssetsBDMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 2.43 indicates that BDMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.43, BDMD is doing good in the industry, outperforming 64.74% of the companies in the same industry.
BDMD has a Debt/Equity ratio of 0.52. This is a neutral value indicating BDMD is somewhat dependend on debt financing.
BDMD's Debt to Equity ratio of 0.52 is on the low side compared to the rest of the industry. BDMD is outperformed by 62.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 2.43
ROIC/WACCN/A
WACCN/A
BDMD Yearly LT Debt VS Equity VS FCFBDMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

BDMD has a Current Ratio of 0.02. This is a bad value and indicates that BDMD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.02, BDMD is doing worse than 98.95% of the companies in the same industry.
BDMD has a Quick Ratio of 0.02. This is a bad value and indicates that BDMD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.02, BDMD is doing worse than 98.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
BDMD Yearly Current Assets VS Current LiabilitesBDMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

BDMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -723.44%.
EPS 1Y (TTM)-723.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDMD Price Earnings VS Forward Price EarningsBDMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDMD Per share dataBDMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAIRD MEDICAL INVESTMENT HOL

NASDAQ:BDMD (5/2/2025, 8:00:01 PM)

After market: 5.5 +0.08 (+1.57%)

5.415

-0.14 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap140.52M
AnalystsN/A
Price TargetN/A
Short Float %0.12%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 56.14
P/tB 56.14
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.85%
ROE -194.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.55%
ROA(5y)N/A
ROE(3y)-9.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 2.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-723.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.45%
OCF growth 3YN/A
OCF growth 5YN/A